Full-Time

Medical Director

Dermatology

Updated on 9/13/2026

Deadline 10/19/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

Compensation Overview

$178.5k - $257.8k/yr

Cambridge, MA, USA + 1 more

More locations: Morristown, NJ, USA

Remote

PharmD, PhD, MD

Category
Biology & Biotech
Required Skills
FDA Regulations
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • An advanced degree in life sciences or pharmaceutical sciences, specifically a PhD, PharmD, PA, NP, or MD with relevant experience.
  • At least 5 years of relevant experience in Medical Affairs.
  • A strong track record of developing and executing medical strategies in the United States.
  • Industry experience in Medical Affairs and/or Clinical Development, with significant experience in Medical Affairs launch and lifecycle management activities.
  • A high degree of knowledge of relevant healthcare systems, the evolving medical landscape, regulatory and payer environments, public health, and industry trends.
  • Sound scientific and clinical judgment, including an in-depth understanding of the scientific method and clinical applications based on medical, scientific, and practical rationale.
  • The ability to understand and effectively communicate scientific and medical data results and information to internal and external stakeholders.
  • Knowledge of pharmacovigilance and local regulatory processes.
  • Digital literacy.
Responsibilities
  • Develop strategy and tactics for an integrated Medical Plan and annual budget for assigned Dermatology products, covering Medical Science Liaisons, Medical Education, Medical Communications and Publications, Health Outcomes, Safety, and Clinical Research including Phase IIIB-IV and Investigator Sponsored Trials.
  • Execute the Integrated Medical Plan to ensure on-time and on-budget delivery of tactical activities and deliverables.
  • Communicate the details and progress of the Medical Plan to Management, the Core Team, and parties responsible for execution.
  • Provide relevant data evidence to ensure that strategy is clearly defined and consistent with clinical development and commercial strategic objectives.
  • Support the generation and communication of scientific and medical insights to internal stakeholders and develop and execute strategic and tactical Medical Engagement Plans.
  • Provide medical strategy and expertise to Clinical, Commercial, Market Access, and Regulatory partners.
  • Ensure strategic and cross-functional alignment across the organization and joint ventures to support the safe and appropriate use of Dermatology products.
  • Provide medical leadership and expertise to sales, marketing, legal, and regulatory functions for marketed products and drugs in development.
  • Collaborate with field, marketing, health economics and value assessment, Market Access, and sales teams.
  • Manage MSL resources and budgets.
  • Partner with Field Medical Head, Medical Directors, and internal partners to manage high-level regional stakeholder relationships, contribute to medical engagement planning, and oversee the MSL budget.
  • Collaborate with the health economics team to address questions and opportunities.
  • Provide medical review and approval of promotional and medical materials in compliance with corporate standards and government and industry regulations.
  • Review and approve medical and scientific content of Regulatory, Safety, Scientific Affairs, Medical Affairs, and Commercial materials.
  • Provide medical review of applications for independent medical education grants.
  • Provide medical review of training materials for medical and commercial employees.
  • Maintain up-to-date working knowledge of and adherence to applicable guidance, regulations, and laws, including FDA, OIG, DDMAC/OPDP, PhRMA, ICMJE, and ISPOR requirements.
  • Support United States Phase IIIB-IV clinical study programs, including preparation of study protocols, case report forms, study reports, statistical analysis plans, clinical trial guidelines, and accurate and timely reporting of study data.
  • Oversee the conduct of clinical studies in adherence to company standards and government and industry regulations, including GCP/ICH.
  • Review and approve Investigator Sponsored Trial concepts and protocols according to applicable standard operating procedures.
  • Identify and co-create research collaboration opportunities within the therapeutic area to address key questions in patient care.
  • Identify needs for post-marketing clinical trials and registries and oversee their management and execution.
  • Ensure company-generated and investigator-sponsored trial data are publicly presented appropriately, timely, fairly, and in a balanced manner.
  • Partner with United States Drug Safety in managing clinical trial adverse events, post-marketing safety data, and communication of identified safety signals.
  • Identify and communicate Product Alerts to the Core Team in conjunction with United States Drug Safety, USRAMP, and GMA.
  • Develop and maintain professional relationships with key thought leaders among physicians and researchers in the medical and scientific community.
  • Lead medical and scientific advisory board discussions to identify and elevate medically focused opportunities, resources, and strategic action within Dermatology.
  • Foster external scientific advisory boards and assist in advocacy development.
  • Interact with experts at medical meetings, advisory boards, and outreach meetings to represent Sanofi and strengthen its reputation in Dermatology.
  • Provide disease-state and product training to internal and external stakeholders.
  • Remain informed of current developments in Dermatology medical and scientific communities through current literature, meetings, conventions, and professional associations.
  • Perform other duties as assigned.
Desired Qualifications
  • Clinical or Medical Affairs experience in Dermatology and/or Immunology is strongly preferred.
  • Experience in clinical trial design and execution is preferred.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.